Patents Represented by Attorney, Agent or Law Firm Alan J. Grant
  • Patent number: 6833356
    Abstract: The invention is directed to isolated polypeptides bearing sequence homology to the Sp36 protein found in pneumococcal organisms, such as Streptococcus pneumoniae. Polynucleotides encoding such polypeptides are also disclosed. The invention also relates to antibodies specific for the disclosed polypeptides and to uses of such antibodies in the treatment of diseases caused by staphylococci as well as group A and B streptococci. In addition, the invention relates to the use of the disclosed polypeptides in compositions and as vaccines and for prophylactic uses such as in vaccination of animals, especially humans, against a wide variety of streptococcal, staphylococcal and other diseases.
    Type: Grant
    Filed: August 25, 2000
    Date of Patent: December 21, 2004
    Assignee: Medimmune, Inc.
    Inventors: Scott Koenig, Jon Heinrichs, Leslie S. Johnson, John E. Adamou
  • Patent number: 6824989
    Abstract: A purified or highly pure recombinant monoclonal antibody with 4G10-hybridoma type specificity is disclosed along with polynucleotides, including cDNA sequences, encoding the antibody chains and the amino acid sequences corresponding to said cDNA polynucleotides and uses for said sequences. Also disclosed are corresponding tagged sequences useful in molecular biological techniques and uses for said sequences.
    Type: Grant
    Filed: September 1, 2000
    Date of Patent: November 30, 2004
    Assignee: Upstate Biotechnology, Inc.
    Inventors: Dominic Eisinger, Lynn Stiles, Arthur LaMarche, Thomas Jelinek
  • Patent number: 6811986
    Abstract: The present invention provides a novel method for ligation of oligonucleotides containing 5′-phosphorothioates on complementary templates by the action of DNA ligases. This reaction is readily applied to the synthesis of a single stranded circular DNA containing a phosphorothioate linkage at the site of ligation junction. The efficiency of 5′-phosphorothioate directed ligation reaction by ATP dependent DNA ligase reaction is similar to conventional 5′-phosphate ligation. The utility of enzymatic ligation in probing specific sequences of DNA is also described. The present invention also provides a novel non-enzymatic ligation of 5′-phosphorothioates that has been applied to the synthesis of single strand phosphorothioate and phosphate circular DNA.
    Type: Grant
    Filed: June 19, 2003
    Date of Patent: November 2, 2004
    Assignee: Molecular Staging, Inc.
    Inventors: Rajanikanth Bandaru, Gyanendra Kumar
  • Patent number: 6777183
    Abstract: Disclosed are methods for allele discrimination involving the use of rolling circle amplification (RCA) coupled with primer extension and utilizing exonuclease deficient polymerases to distinguish matched and unmated single nucleotide sites, such as in the case of a single nucleotide polymorphism (SNP).
    Type: Grant
    Filed: April 5, 2001
    Date of Patent: August 17, 2004
    Assignee: Molecular Staging, Inc.
    Inventor: Patricio AbarzĂșa
  • Patent number: 6759208
    Abstract: High throughput screening assays for the identification of potential therapeutic agents able to modulate the activity of enzymes of fatty acid biosynthesis, especially desaturases and/or elongases, are disclosed along with therapeutic uses of the agents identified by such assays for the prevention and/or treatment of diseases related to fatty acid metabolism. Substrates useful in such assays are also described.
    Type: Grant
    Filed: August 29, 2002
    Date of Patent: July 6, 2004
    Assignee: Xenon Genetics Inc.
    Inventors: Michael D. Winther, Mark P. Gray-Keller
  • Patent number: 6737063
    Abstract: The present invention provides bacterial immunogenic agents for administration to humans and non-human animals to stimulate an immune response. Also provided are methods for vaccination of mammalian species, especially human patients, with variants of the E. coli FimH protein, said variants being derived from different strains of E. coli, and to production of antibodies that protect the vaccine recipient against infection by pathogenic bacterial species. In another aspect the invention provides antibodies against such proteins and protein complexes that may be used as diagnostics and/or as protective/treatment agents for pathogenic bacterial species. A plasmid-based method of producing polypeptides, especially fused polypeptides, such as the complex of a bacterial chaperone and a bacterial adhesin, is also disclosed.
    Type: Grant
    Filed: July 6, 2001
    Date of Patent: May 18, 2004
    Assignee: MedImmune, Inc.
    Inventors: Solomon Langermann, Andrew Revel, Christine Auguste, Jeanne Burlein
  • Patent number: 6689369
    Abstract: The present invention relates to novel immunogenic polypeptides, and therapeutically active fragments thereof, and vaccines, and vaccine compositions, for the prevention and treatment of streptococcal infection, especially by Streptococcus pneumoniae. The invention also relates to antibodies against the disclosed polypeptides, as well as methods of disease prevention and/or treatment.
    Type: Grant
    Filed: April 27, 2001
    Date of Patent: February 10, 2004
    Assignee: MedImmune, Inc.
    Inventors: Scott Koenig, Leslie S. Johnson, John E. Adamou
  • Patent number: 6670151
    Abstract: This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production and isolation of such polynucleotides and polypeptides. More particularly, the polynucleotides and polypeptides of the present invention have been identified as porcine stem cell factors, and in particular membrane-bound porcine stem cell factors, and still more particularly as being involved in the culture of pluripotent or totipotent porcine cells.
    Type: Grant
    Filed: April 25, 2000
    Date of Patent: December 30, 2003
    Assignee: BioTransplant, Inc.
    Inventor: Manfred Baetscher
  • Patent number: 6656467
    Abstract: Ultra high affinity antibodies with binding affinities in the range of 1010 M−1, and even 1011 M−1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such antibodies, as well as methods of using them to prevent and/or treat disease, especially virus-induced diseases, are also disclosed.
    Type: Grant
    Filed: January 26, 2001
    Date of Patent: December 2, 2003
    Assignees: MedImmune, Inc., Applied Molecular Evolution
    Inventors: James F. Young, Leslie S. Johnson, William D. Huse, Herren Wu, Jeffry D. Watkins
  • Patent number: 6617122
    Abstract: The invention features ABC1 nucleic acids and polypeptides for the diagnosis and treatment of abnormal cholesterol regulation. The invention also features methods for identifying compounds for modulating cholesterol levels in an animal (e.g., a human).
    Type: Grant
    Filed: March 15, 2000
    Date of Patent: September 9, 2003
    Assignee: Xenon Genetics, Inc.
    Inventors: Michael R. Hayden, Angela R. Brooks-Wiison, Simon N. Pimstone
  • Patent number: 6582706
    Abstract: A vaccine composition is disclosed that comprises polypeptides and fragments of polypeptides containing histidine triad residues or coiled-coil regions, some of which polypeptides or fragments lie between 80 and 680 residues in length. Also disclosed are processes for preventing infection caused by S. pneumoniae comprising administering of vaccine compositions.
    Type: Grant
    Filed: December 21, 1999
    Date of Patent: June 24, 2003
    Assignee: MedImmune, Inc.
    Inventors: Leslie S. Johnson, John E. Adamou
  • Patent number: 6565849
    Abstract: Disclosed are methods for vaccine priming, using co-treatment, at a temporally similar or at a previous time, with a priming antibody capable of priming, or enhancing, or potentiating the effects of a vaccine, or vaccine composition. Also disclosed are methods of using this process to prevent or treat disease.
    Type: Grant
    Filed: March 2, 2001
    Date of Patent: May 20, 2003
    Assignee: MedImmune, Inc.
    Inventor: Scott Koenig
  • Patent number: 6548539
    Abstract: Compounds of the general structure according to Formula (I) wherein R1 is selected from alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, and heterocycloalkyl; R2 is selected from alkyl, alkenyl, alkyny, heteroalkyl, haloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl; R3 is selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl; W is selected from Ch2, O and S; n is 0 to about 3: X is selected from S or O; Y, if present, is selected from a bond, aryl, NH, NR, O or S, where R3 is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl; and Z, if present, can represent a bond or is selected from lower alkyl, O or S are disclosed. Also disclosed are uses of such compounds for treating a variety of disease conditions, including cancer.
    Type: Grant
    Filed: March 5, 2002
    Date of Patent: April 15, 2003
    Assignee: Avalon Pharmaceuticals
    Inventors: Stanislaw Pikul, Daniel R. Soppet, Paul E. Young
  • Patent number: 6503511
    Abstract: The present invention provides bacterial immunogenic agents for administration to humans and non-human animals to stimulate an immune response. It particularly relates to the vaccination of mammalian species with pneumococcal derived polypeptides that include an alpha helix but exclude a choline binding region as a mechanism for stimulating production of antibodies that protect the vaccine recipient against infection by pathogenic bacterial species. In another aspect the invention provides antibodies against such proteins and protein complexes that may be used as diagnositics and/or as protective/treatment agents for pathogenic bacterial species.
    Type: Grant
    Filed: April 6, 1999
    Date of Patent: January 7, 2003
    Assignee: MedImmune, Inc.
    Inventors: Theresa M. Wizemann, Scott Koenig, Leslie S. Johnson
  • Patent number: 6500434
    Abstract: The present invention provides bacterial immunogenic agents for administration to humans and non-human animals to stimulate an immune response. It particularly relates to the vaccination of mammalian species with heteropolymeric protein complexes as a mechanism for stimulating production of antibodies that protect the vaccine recipient against infection by pathogenic bacterial species. In another aspect the invention provides antibodies against such proteins and protein complexes that may be used as diagnostics and/or as protective/treatment agents for pathogenic bacterial species. A novel vector for expressing the FimC-H complex at optimal levels is also disclosed.
    Type: Grant
    Filed: April 23, 1999
    Date of Patent: December 31, 2002
    Assignee: MedImmune, Inc.
    Inventors: Solomon Langermann, Scott J. Hultgren, Jerome S. Pinkner, Christine Gale Auguste
  • Patent number: 6498023
    Abstract: The present invention provides a method for the rapid simultaneous production of a plurality of single-stranded DNA circles having a predetermined size and nucleotide sequence using pre-designed hairpin oligonucleotides containing complementary sequences for directing ligation to form dumbbell-shaped monomers followed by heat denaturation to yield single-stranded DNA circles.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: December 24, 2002
    Assignee: Molecular Staging, Inc.
    Inventor: Patricio AbarzĂșa
  • Patent number: 6482937
    Abstract: The present invention provides for a method of isolating and/or propagating porcine stem cells, more specifically pluripotential porcine embryonic stem cells. The pluripotential cells are isolated and/or propagated by the use of a selectable marker gene which is inserted into the genetic material of the cells, and which permits the survival and growth of the porcine embryonic stem cells. The selectable marker gene is inserted so as to be regulated by a control or promoter polynucleotide sequence in the embryonic stem cells, for example the promoter polynucleotide sequence being the porcine Oct-4 promoter sequence of the present invention. The invention also provides for a transgenic pig which will constitute a source of the pluripotent cells.
    Type: Grant
    Filed: October 9, 1997
    Date of Patent: November 19, 2002
    Assignee: BioTransplant, Inc.
    Inventors: Manfred W. Baetscher, Donna E. Akiyoshi, Ruth A. Kaplan
  • Patent number: 6461811
    Abstract: Isolated polynucleotides and polypeptides derived from the genome of swine gamma-herpesviruses are disclosed, including recombinant cells and vectors encoding such polypeptides and expressing such polynucleotides. Use of the novel polynucleotides as probes of the swine genome is also described. Assay methods employing antibodies against the isolated polypeptides are also disclosed.
    Type: Grant
    Filed: July 7, 2000
    Date of Patent: October 8, 2002
    Assignee: BioTransplant, Inc.
    Inventor: Clive Patience
  • Patent number: 6376235
    Abstract: The present invention provides polynucleotides coding for the mature transcriptional regulators known as ivi-2 and ivi-3, as well as a polynucleotide coding for a polypeptide designated as ivi-4. The polynucleotides were obtained from a genomic library obtained from the bacterial species Enterococcus faecalis.
    Type: Grant
    Filed: March 16, 1999
    Date of Patent: April 23, 2002
    Assignee: Avant Immunotherapeutics, Inc.
    Inventor: David Beattie
  • Patent number: 6368599
    Abstract: The present invention provides immunogenic compositions and methods for inducing enhanced immune responses using an antigen by use of an adjuvant comprising a member selected from a Caulobacter (in particular, C. crescentus) LPS or a fragment or derivative thereof.
    Type: Grant
    Filed: February 22, 2000
    Date of Patent: April 9, 2002
    Assignee: Univ. of British Columbia
    Inventors: Solomon Langermann, Scott Koenig, John Smit, Nilofer Qureshi